Received for publication April 12, 2005.
Revised May 7, 2005.
Accepted for publication May 10, 2005.

CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY

Abstract

Genetic polymorphisms of CYP2A6 gene are known as a causal factor of the interindividual differences in nicotine metabolism. We found three novel CYP2A6 alleles. The CYP2A6*18A allele has a single nucleotide polymorphism (SNP) of A5668T (A1175T, Y392F) in exon 8. The CYP2A6*18B allele has synonymous SNPs of G51A (G51A), T5684C (T1191C), and T5702C (T1209C) in addition to A5668T (A1175T, Y392F). The CYP2A6*19 allele has the SNPs of A5668T (A1175T, Y392F), T6354C (intron 8), and T6558C (T1412C, I471T) as well as the conversion with the CYP2A7 sequence in the 3'-untranslated region, in which the latter two changes correspond to CYP2A6*7. Ethnic differences in the frequencies of these alleles were observed between Caucasians, African-Americans, and Japanese. Wild or variant CYP2A6 (CYP2A6*18, CYP2A6*19, and CYP2A6*7) were expressed in Escherichia coli. For coumarin 7-hydroxylation and 5-fluorouracil formation from tegafur, the Km values were increased and Vmax values were decreased in CYP2A6.18 compared with those in CYP2A6.1, resulting in decreased clearance to 50% and 35 % of that of the wild type, respectively. The Km and Vmax values for nicotine C-oxidation were both increased, resulting in no change of clearance. In CYP2A6.19, the effects on the coumarin 7-hydroxylation and 5-fluorouracil formation (increased Km and decreased Vmax) were prominent, resulting in decreased clearance to 8% of those of the wild type. For nicotine C-oxidation, the Km and Vmax values were both decreased, resulting in decreased clearance to 30% of that of the wild type. The changes of the kinetics in CYP2A6.19 were similar to those in CYP2A6.7. In vivo nicotine metabolism was evaluated in Caucasians (n = 56) and Koreans (n = 40). Although the CYP2A6*18 and CYP2A6*19 alleles were found only heterozygously, a subject with CYP2A6*7/CYP2A6*19 showed a lower cotinine/nicotine ratio of the plasma concentration compared with homozygotes of the CYP2A6*1A, supporting the in vitro results that the CYP2A6*19 allele leads to decreased enzymatic activity.

Key words: CYP2A, genetic polymorphism, genotype, human CYP enzymes

This article has been cited by other articles:

				T. Fukami, M. Nakajima, H. Yamanaka, Y. Fukushima, H. L. Mcleod, and T. Yokoi A Novel Duplication Type of CYP2A6 Gene in African-American Population Drug Metab. Dispos., April 1, 2007; 35(4): 515 - 520. [Abstract] [Full Text] [PDF]

				M. Nakajima, M. Itoh, H. Yamanaka, T. Fukami, S. Tokudome, Y. Yamamoto, H. Yamamoto, and T. Yokoi Isoflavones Inhibit Nicotine C-Oxidation Catalyzed by Human CYP2A6. J. Clin. Pharmacol., March 1, 2006; 46(3): 337 - 344. [Abstract] [Full Text] [PDF]